Lectures and seminars OnkPat Friday Seminar: In Vivo Dendritic Cell Reprogramming for Melanoma and Beyond

Host: Kasper Karlsson, Department of Oncology-Pathology

Bio

Filipe Pereira, Ph.D. is a Full Professor of Molecular Medicine at Lund University’s Faculty of Medicine in Sweden. He is internationally recognized for pioneering work at the intersection of cellular reprogramming and immunology, particularly in the development of reprogramming-based immunotherapies.

Over the past two decades, he has contributed to the fields of cellular reprogramming and hematopoietic specification. During his Ph.D. at Imperial College London, he employed cell fusion and heterokaryon models to study mechanisms of reprogramming toward pluripotency. As a postdoctoral researcher at the Icahn School of Medicine at Mount Sinai, he was the first to apply reprogramming concepts to hematopoiesis. 

He established his first independent group at Coimbra University in 2015 before moving to Lund University in 2017, where he uncovered novel mechanisms underlying hematopoietic reprogramming and definitive hematopoiesis. He also pioneered reprogramming approaches in immunology by inducing dendritic cells from fibroblasts and cancer cells, introducing a new paradigm that bridges reprogramming with cancer immunotherapy. This work led to the founding of Asgard Therapeutics, which has secured €36 million in funding from leading venture capital firms to bring in vivo dendritic cell reprogramming to cancer patients.

His scientific achievements, along with his innovation efforts, have been recognized with numerous awards, including ERC Consolidator and Proof-of-Concept Grants, the Swedish Research Council Consolidator Grant, and the Novo Nordisk Foundation Distinguished Innovator Grant. He is a fellow of the Swedish Wallenberg Program in Molecular Medicine and serves as Editor-in-Chief of Cellular Reprogramming. Additional honors include the Swedish Fernström Prize for young investigators, the Pfizer-Portugal Basic Research Award, the Imperial College Emerging Alumni Leader Award, the Mount Sinai-KiiLN Entrepreneurship Award, and a Medal of Merit from his hometown in Portugal.

Relaterade publikationer

Anchored screening identifies transcription factor blueprints underlying dendritic cell diversity and subset-specific anti-tumor immunity.
Henriques-Oliveira L, Altman AR, Kurochkin I, Ascic E, Halitzki E, Matei AM, Pértiga-Cabral D, Ulmert I, Holst S, Nair MS, Cunha PP, Park SM, Vergani S, Kharas MG, Yuan J, Lahl K, Rosa FF, Pires CF, Pereira CF
Immunity 2025 Aug;():

In vivo dendritic cell reprogramming for cancer immunotherapy.
Ascic E, Åkerström F, Sreekumar Nair M, Rosa A, Kurochkin I, Zimmermannova O, Catena X, Rotankova N, Veser C, Rudnik M, Ballocci T, Schärer T, Huang X, de Rosa Torres M, Renaud E, Velasco Santiago M, Met Ö, Askmyr D, Lindstedt M, Greiff L, Ligeon LA, Agarkova I, Svane IM, Pires CF, Rosa FF, Pereira CF
Science 2024 Oct;386(6719):eadn9083

Restoring tumor immunogenicity with dendritic cell reprogramming.
Zimmermannova O, Ferreira AG, Ascic E, Velasco Santiago M, Kurochkin I, Hansen M, Met Ö, Caiado I, Shapiro IE, Michaux J, Humbert M, Soto-Cabrera D, Benonisson H, Silvério-Alves R, Gomez-Jimenez D, Bernardo C, Bauden M, Andersson R, Höglund M, Miharada K, Nakamura Y, Hugues S, Greiff L, Lindstedt M, Rosa FF, Pires CF, Bassani-Sternberg M, Svane IM, Pereira CF
Sci Immunol 2023 Jul;8(85):eadd4817

GATA2 mitotic bookmarking is required for definitive haematopoiesis.
Silvério-Alves R, Kurochkin I, Rydström A, Vazquez Echegaray C, Haider J, Nicholls M, Rode C, Thelaus L, Lindgren AY, Ferreira AG, Brandão R, Larsson J, de Bruijn MFTR, Martin-Gonzalez J, Pereira CF
Nat Commun 2023 Aug;14(1):4645

Task delegation to physician extenders--some comparisons.
Glenn JK, Goldman J
Am J Public Health 1976 Jan;66(1):64-6

Direct reprogramming of fibroblasts into antigen-presenting dendritic cells.
Rosa FF, Pires CF, Kurochkin I, Ferreira AG, Gomes AM, Palma LG, Shaiv K, Solanas L, Azenha C, Papatsenko D, Schulz O, Reis e Sousa C, Pereira CF
Sci Immunol 2018 Dec;3(30):